EGFR and neoplasm: In vivo and in vitro experiments on NSCLC and TNBC showed that EGFR/Notch-bispecific mAbs exhibit potent anti-tumor effects, especially decreasing the abundance of CSCs, which limits tumor resistance to EGFR-TKIs and has potential value for clinical applications (Hu et al., 2017; Fu et al., 2019).